169 related articles for article (PubMed ID: 31219972)
1. Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report.
Stueger A; Winder T; Tinguely M; Petrausch U; Helbling D
J Immunother; 2019 Sep; 42(7):274-277. PubMed ID: 31219972
[TBL] [Abstract][Full Text] [Related]
2. PD-1 blockade in deficient mismatch repair mixed adenoneuroendocrine carcinoma of the stomach: new hope for an orphan disease.
Riccò B; Salati M; Reggiani Bonetti L; Dominici M; Luppi G
Tumori; 2020 Dec; 106(6):NP57-NP62. PubMed ID: 32878569
[TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report.
Song HN; Kang MG; Park JR; Hwang JY; Kang JH; Lee WS; Lee GW
Cancer Res Treat; 2018 Oct; 50(4):1458-1461. PubMed ID: 29361819
[TBL] [Abstract][Full Text] [Related]
5. [Poorly differentiated endocrine carcinoma of the colon].
Saint-Blancard P; Hervouet M; Chapuis O
Rev Med Interne; 2010 Jun; 31(6):e10-2. PubMed ID: 20167397
[TBL] [Abstract][Full Text] [Related]
6. Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report.
Semrau S; Agaimy A; Pavel M; Lubgan D; Schmidt D; Cavallaro A; Golcher H; Grützmann R; Fietkau R
J Med Case Rep; 2019 Mar; 13(1):82. PubMed ID: 30902067
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy.
Zhou Y; Lin Z; Zhang X; Chen C; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2019 May; 7(1):120. PubMed ID: 31053172
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review.
Muramatsu-Maekawa Y; Taniguchi T; Ito H; Nakane K; Kato T; Tsuchiya T; Miyazaki T; Koie T; Mizutani K
J Immunother; 2020 May; 43(4):134-138. PubMed ID: 32080020
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.
Wang VE; Urisman A; Albacker L; Ali S; Miller V; Aggarwal R; Jablons D
J Immunother Cancer; 2017 Sep; 5(1):75. PubMed ID: 28923100
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab in the treatment of advanced urothelial cancer.
Lundgren KT; Farina MS; Bellmunt J
Future Oncol; 2017 Dec; 13(30):2745-2758. PubMed ID: 29219016
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
Goldstein DA; Bilal U; Prasad V
Cancer; 2017 Oct; 123(20):3872-3874. PubMed ID: 28662268
[No Abstract] [Full Text] [Related]
12. Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
Quaas A; Waldschmidt D; Alakus H; Zander T; Heydt C; Goeser T; Daheim M; Kasper P; Plum P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Göbel H; Tharun L; Buettner R; Merkelbach-Bruse S
BMC Gastroenterol; 2018 May; 18(1):75. PubMed ID: 29855275
[TBL] [Abstract][Full Text] [Related]
13. [A case of mixed adenoneuroendocrine carcinoma of the transverse colon].
Kusakabe J; Miki A; Kobayashi H; Uryuhara K; Hashida H; Mizumoto M; Kaihara S; Hosotani R; Yamashita D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1826-8. PubMed ID: 25731343
[TBL] [Abstract][Full Text] [Related]
14. Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer.
Hoffner B; Leighl NB; Davies M
Cancer Treat Rev; 2020 Apr; 85():101979. PubMed ID: 32078962
[TBL] [Abstract][Full Text] [Related]
15. Oncologic outcome of mixed adenoneuroendocrine carcinoma (MANEC): A single center case series.
Dulskas A; Pilvelis A
Eur J Surg Oncol; 2020 Jan; 46(1):105-107. PubMed ID: 31444026
[TBL] [Abstract][Full Text] [Related]
16. [Mixed adenoneuroendocrine carcinoma with multiple liver metastases successfully treated by cetuximab/CPT-11 chemotherapy followed by curative resection - a case report].
Tani K; Seyama Y; Inada K; Matsuoka Y; Takahashi M; Tanizawa T; Warabi M; Nasu K; Wada I; Maeshiro T; Miyamoto S; Umekita N
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2145-7. PubMed ID: 25731451
[TBL] [Abstract][Full Text] [Related]
17. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
[TBL] [Abstract][Full Text] [Related]
18. Mixed adenoneuroendocrine carcinoma of the colon progressed rapidly after hepatic rupture: report of a case.
Ito H; Kudo A; Matsumura S; Ban D; Irie T; Ochiai T; Nakamura N; Tanaka S; Tanabe M
Int Surg; 2014; 99(1):40-4. PubMed ID: 24444267
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological features of an ascending colon mixed adenoneuroendocrine carcinoma with clinical serosal invasion.
Liu XJ; Feng JS; Xiang WY; Kong B; Wang LM; Zeng JC; Liang YF
Int J Clin Exp Pathol; 2014; 7(9):6395-8. PubMed ID: 25337298
[TBL] [Abstract][Full Text] [Related]
20. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
Beck TN; Kudinov AE; Dulaimi E; Boumber Y
BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
